| Literature DB >> 30885899 |
Katharina Schaufler1,2, Torsten Semmler3, Jukka Corander4,5,6, Sebastian Guenther7,8, Lothar H Wieler9, Darren J Trott10, Johann Pitout11,12, Gisele Peirano11,12, Jonas Bonnedahl13,14, Monika Dolejska15,16, Ivan Literak15,16, Stephan Fuchs17, Niyaz Ahmed18, Mirjam Grobbel19, Carmen Torres20, Alan McNally21, Derek Pickard4, Christa Ewers22, Nicholas J Croucher23.
Abstract
The pathogenic extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli lineage ST648 is increasingly reported from multiple origins. Our study of a large and global ST648 collection from various hosts (87 whole-genome sequences) combining core and accessory genomics with functional analyses and in vivo experiments suggests that ST648 is a nascent and generalist lineage, lacking clear phylogeographic and host association signals. By including large numbers of ST131 (n = 107) and ST10 (n = 96) strains for comparative genomics and phenotypic analysis, we demonstrate that the combination of multidrug resistance and high-level virulence are the hallmarks of ST648, similar to international high-risk clonal lineage ST131. Specifically, our in silico, in vitro, and in vivo results demonstrate that ST648 is well equipped with biofilm-associated features, while ST131 shows sophisticated signatures indicative of adaption to urinary tract infection, potentially conveying individual ecological niche adaptation. In addition, we used a recently developed NFDS (negative frequency-dependent selection) population model suggesting that ST648 will increase significantly in frequency as a cause of bacteremia within the next few years. Also, ESBL plasmids impacting biofilm formation aided in shaping and maintaining ST648 strains to successfully emerge worldwide across different ecologies. Our study contributes to understanding what factors drive the evolution and spread of emerging international high-risk clonal lineages.Entities:
Keywords: ESBL-producing clonal lineages; MDR; NFDS modeling; ST648; biofilm formation; phylogenetics; virulence
Year: 2019 PMID: 30885899 PMCID: PMC6535536 DOI: 10.1128/AAC.00243-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191